|
1
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rochefort MM, Ankeny JS, Kadera BE, Donald
GW, Isacoff W, Wainberg ZA, Hines OJ, Donahue TR, Reber HA and
Tomlinson JS: Impact of tumor grade on pancreatic cancer prognosis:
Validation of a novel TNMG staging system. Ann Surg Oncol.
20:4322–4329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koliopanos A, Avgerinos C, Farfaras A,
Manes C and Dervenis C: Radical resection of pancreatic cancer.
Hepatobiliary Pancreat Dis Int. 7:11–18. 2008.PubMed/NCBI
|
|
5
|
Abe M, Kondo S, Hirano S, Ambo Y, Tanaka
E, Morikawa T, Okushiba S and Katoh H: Long-term survival after
radical resection of advanced pancreatic cancer: A case report with
special reference to CD8+ T-cell infiltration. Int J
Gastrointest Cancer. 33:107–110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lowenfels AB and Maisonneuve P:
Epidemiology and risk factors for pancreatic cancer. Best Pract Res
Clin Gastroenterol. 20:197–209. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kashiwagi Y, Kato N, Sassa T, Nishitsuka
K, Yamamoto T, Takamura H and Yamashita H: Cotylenin A inhibits
cell proliferation and induces apoptosis and PAX6 mRNA transcripts
in retinoblastoma cell lines. Mol Vis. 16:970–982. 2010.PubMed/NCBI
|
|
8
|
Tchernitsa O, Kasajima A, Schäfer R, Kuban
RJ, Ungethüm U, Györffy B, Neumann U, Simon E, Weichert W, Ebert
MP, et al: Systematic evaluation of the miRNA-ome and its
downstream effects on mRNA expression identifies gastric cancer
progression. J Pathol. 222:310–319. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He B, Li T, Guan L, Liu FE, Chen XM, Zhao
J, Lin S, Liu ZZ and Zhang HQ: CTNNA3 is a tumor suppressor in
hepatocellular carcinomas and is inhibited by miR-425. Oncotarget.
7:8078–8089. 2016.PubMed/NCBI
|
|
10
|
Li L, Chen HZ, Chen FF, Li F, Wang M, Wang
L, Li YQ and Gao DS: Global microRNA expression profiling reveals
differential expression of target genes in
6-hydroxydopamine-injured MN9D cells. Neuromolecular Med.
15:593–604. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu J, Li A, Hong SM, Hruban RH and Goggins
M: MicroRNA alterations of pancreatic intraepithelial neoplasias.
Clin Cancer Res. 18:981–992. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding C, Xu J and Li J: ABT-874, a fully
human monoclonal anti-IL-12/IL-23 antibody for the potential
treatment of autoimmune diseases. Curr Opin Investig Drugs.
9:515–522. 2008.PubMed/NCBI
|
|
13
|
Langowski JL, Zhang X, Wu L, Mattson JD,
Chen T, Smith K, Basham B, McClanahan T, Kastelein RA and Oft M:
IL-23 promotes tumour incidence and growth. Nature. 442:461–465.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using realtime quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Z, Wen M, Guo J, Shi J, Wang Z, Tan
B, Zhang G, Zheng X and Zhang A: Clinical value of miR-425-5p
detection and its association with cell proliferation and apoptosis
of gastric cancer. Pathol Res Pract. 213:929–937. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ciric B, El-behi M, Cabrera R, Zhang GX
and Rostami A: IL-23 drives pathogenic IL-17-producing
CD8+ T cells. J Immunol. 182:5296–5305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shime H, Yabu M, Akazawa T, Kodama K,
Matsumoto M, Seya T and Inoue N: Tumor-secreted lactic acid
promotes IL-23/IL-17 proinflammatory pathway. J Immunol.
180:7175–7183. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen G, Liang Y, Guan X, Chen H, Liu Q,
Lin B, Chen C, Huang M, Chen J, Wu W, et al: Circulating low IL-23:
IL-35 cytokine ratio promotes progression associated with poor
prognosisin breast cancer. Am J Transl Res. 8:2255–2264.
2016.PubMed/NCBI
|
|
20
|
Khodadadi A, Razmkhah M, Eskandari AR,
Hosseini A, Habibagahi M, Ghaderi A and Jaberipour M: IL-23/IL-27
ratio in peripheral blood of patients with breast cancer. Iran J
Med Sci. 39:350–356. 2014.PubMed/NCBI
|
|
21
|
Sun L, Jiang R, Li J, Wang B, Ma C, Lv Y
and Mu N: MicoRNA-425-5p is a potential prognostic biomarker for
cervical cancer. Ann Clin Biochem. 54:127–133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Petanidis S, Anestakis D, Argyraki M,
Hadzopoulou-Cladaras M and Salifoglou A: Differential expression of
IL-17, 22 and 23 in the progression of colorectal cancer in
patients with K-ras mutation: Ras signal inhibition and crosstalk
with GM-CSF and IFN-γ. PLoS One. 8:e736162013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qian X, Gu L, Ning H, Zhang Y, Hsueh EC,
Fu M, Hu X, Wei L, Hoft DF and Liu J: Increased Th17 cells in the
tumor microenvironment is mediated by IL-23 via tumor-secreted
prostaglandin E2. J Immunol. 190:5894–5902. 2013. View Article : Google Scholar : PubMed/NCBI
|
